Our top pick for
Kindred Biosciences, Inc is a drug manufacturers-specialty & generic business based in the US. Kindred Biosciences shares (KIN) are listed on the NASDAQ and all prices are listed in US Dollars. Kindred Biosciences employs 156 staff and has a trailing 12-month revenue of around USD$3.9 million.
|Latest market close||USD$3.71|
|52-week range||USD$3.105 - USD$11.93|
|50-day moving average||USD$3.9369|
|200-day moving average||USD$4.1515|
|Wall St. target price||USD$11.18|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.634|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||-23.03%|
|1 month (2020-12-18)||-10.17%|
|3 months (2020-10-16)||-13.52%|
|6 months (2020-07-17)||-10.82%|
|1 year (2020-01-17)||-62.30%|
|2 years (2019-01-18)||-62.34%|
|3 years (2018-01-18)||8.75|
|5 years (2016-01-15)||12.77%|
|Revenue TTM||USD$3.9 million|
|Gross profit TTM||USD$3.7 million|
|Return on assets TTM||-32.39%|
|Return on equity TTM||-31.01%|
|Market capitalisation||USD$183.4 million|
TTM: trailing 12 months
There are currently 712,705 Kindred Biosciences shares held short by investors – that's known as Kindred Biosciences's "short interest". This figure is 3% up from 691,979 last month.
There are a few different ways that this level of interest in shorting Kindred Biosciences shares can be evaluated.
Kindred Biosciences's "short interest ratio" (SIR) is the quantity of Kindred Biosciences shares currently shorted divided by the average quantity of Kindred Biosciences shares traded daily (recently around 195798.07692308). Kindred Biosciences's SIR currently stands at 3.64. In other words for every 100,000 Kindred Biosciences shares traded daily on the market, roughly 3640 shares are currently held short.
However Kindred Biosciences's short interest can also be evaluated against the total number of Kindred Biosciences shares, or, against the total number of tradable Kindred Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kindred Biosciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Kindred Biosciences shares in existence, roughly 20 shares are currently held short) or 0.0235% of the tradable shares (for every 100,000 tradable Kindred Biosciences shares, roughly 24 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kindred Biosciences.
Find out more about how you can short Kindred Biosciences stock.
We're not expecting Kindred Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Kindred Biosciences's shares have ranged in value from as little as $3.105 up to $11.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kindred Biosciences's is 1.2184. This would suggest that Kindred Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.